Nine Catalysts For China Biopharma In 2019

 
• By Brian Yang

After much turmoil in 2018, the biopharma sector in China is embracing multiple uncertainties in the year of the boar.

Shanghai overpass
Shanghai Leads China's Massive "4+7" Centralized Bidding Scheme. • Source: Shutterstock

More from China

More from Focus On Asia